GeneDx Holdings Corp. (WGS) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp.
Is GeneDx Holdings Corp. stock overvalued or undervalued in 2026?
As of October 5, 2026, GeneDx Holdings Corp. (WGS) trades at $73.09 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: GeneDx Holdings Corp.
Market cap $2B · 52 weeks $35 – $168 (54 % below the high) · P/E no earnings · 2027 expected P/E 61.0× · Dividend none · Next earnings October 27, 2026 · expected EPS $0.07 · Price as of Oct 5 · accounts published Aug 3.
- Valuation: P/Sales 3.1× (no earnings).
- Business: ROIC −15 % (weak).
- Balance sheet: Net debt/EBITDA 7.1× (fragile).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in pharma: 1 of 4 pass
- ROIC −14.7 %, fails.
- Net debt / EBITDA 7.1×, fails.
- Gross margin 69.7 %, borderline.
- R&D / Revenue 16.8 %, passes.
Against its peers (reference peers) — GeneDx Holdings Corp.: P/E —; EV/EBITDA —; ROIC -14.7 %; $2.2B. Privia Health Group, Inc. (P/E 90.3×; EV/EBITDA —; ROIC 0.0 %; $2.5B), Option Care Health, Inc. (P/E 17.0×; EV/EBITDA 14.9×; ROIC 9.3 %; $3.4B), Hinge Health, Inc. (P/E 72.5×; EV/EBITDA 71.2×; ROIC 26.3 %; $7.6B).
Profitability
| Return on Equity | -38.72% |
| Return on Invested Capital | -14.69% |
| Return on Assets | -22.09% |
| Gross Margin | 68.20% |
| Operating Margin | -13.34% |
| Net Margin | -23.40% |
Financial Health
| Debt / Equity | 0.69 |
| Current Ratio | 3.30 |
Price Performance
| 1 month | -11.30% |
| 3 months | +16.23% |
| Year-to-date | -41.36% |
| 1 year | -36.54% |
| 3 years | +2197.29% |
| 5 years | -70.67% |
Related companies: HNGE · IMVT · KYMR · NAMS · OPCH · OSCR
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of WGS: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks